We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Laser-Mediated Photodynamic Therapy of Acne Vulgaris and Rosacea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00483145
Recruitment Status : Completed
First Posted : June 6, 2007
Last Update Posted : June 3, 2008
Sponsor:
Information provided by:

Study Description
Brief Summary:
To evaluate efficacy and adverse effect from long-pulsed dye laser versus long-pulsed dye laser-mediated photodynamic therapy for acne vulgaris and rosacea.

Condition or disease Intervention/treatment
Acne Vulgaris and Rosacea Device: Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate) Device: Long-pulsed dye laser Device: Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Official Title: Laser-Mediated Photodynamic Therapy of Acne Vulgaris and Rosacea
Study Start Date : November 2006
Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Rosacea
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: 1
Long-pulsed dye laser (Candela)
Device: Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate) Device: Long-pulsed dye laser
Active Comparator: 2
Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
Device: Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate) Device: Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Inflammatory acne and rosacea
  • Skin types I-IV

Exclusion Criteria:

  • Patients younger than 18 years
  • Skin types V and VI
  • Topical and systemic conventional acne treatments
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483145


Locations
Denmark
Bispebjerg Hospital
Copenhagen NV, Denmark, 2400
Sponsors and Collaborators
Bispebjerg Hospital
Investigators
Principal Investigator: Merete Hædersdal Bispebjerg Hospital
More Information

Responsible Party: Merete Hædersdal, Bispebjerg Hospital
ClinicalTrials.gov Identifier: NCT00483145     History of Changes
Other Study ID Numbers: KF-01-328309
First Posted: June 6, 2007    Key Record Dates
Last Update Posted: June 3, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Acne Vulgaris
Rosacea
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Methyl 5-aminolevulinate
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents